Showing 2431-2440 of 5693 results for "".
- Registration Now Open for International Sports Vision Association 6th Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-6th-annual-conference/2480360/Registration is now open for Elevating Athletic Performance<
- Quantel Medical Launches Website Dedicated to Laser Therapies for Retinal Disordershttps://modernod.com/news/quantel-medical-launches-website-dedicated-to-laser-therapies-for-retinal-disorders/2480357/Quantel Medical announced its new website, www.subliminal-laser-therapy.com, dedicated to laser therapies for retinal disorders. "Over the years, the development and introduction of new and innovative laser technologies has
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh
- Novartis Announces FDA and EMA Filing Acceptances of Beovu for Patients with Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-and-ema-filing-acceptances-of-beovu-for-patients-with-diabetic-macular-edema/2480351/Novartis announced that the FDA has accepted the company’s supplemental biologics license application (BLA) and that the European Medicines Agency (EMA) has validated the type-II variation application for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME).
- Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of Iluvien to Significantly Reduce Treatment Burden in Patients with DMEhttps://modernod.com/news/recent-24-month-real-world-paladin-data-demonstrate-the-ability-of-iluvien-to-significantly-reduce-treatment-burden-in-patients-with-dme/2480348/Alimera Sciences announced a data presentation at the American Society of Retina Specialists (ASRS) demonstrating significant reductions in treatment burden in patients receiving Iluvien for diabetic macular edema (DME). The real-world data from the phase 4 PALADIN study
- Ocular Therapeutix Gains New Indication for Dextenza to Include Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-nabs-new-indication-for-dextenza-to-include-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2480340/Ocular Therapeutix announced the FDA has approved its supplemental new drug application (sNDA) to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, Dextenza is the first, FDA-approve
- CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression After 2 Yearshttps://modernod.com/news/coopervision-sightglass-vision-diffusion-optics-technology-demonstrates-significant-reduction-in-myopia-progression-after-two-years/2480328/CooperVision’s SightGlass Vision Business has revealed 2-year clinical study data for its Diffusion Optics Technology, which is designed to slow the progression of myopia in children.1 After 2 years, children who wore their Diffusion Optics Technology-enabled spectacles full
- Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studieshttps://modernod.com/news/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at-retina-society-annual-meeting/2480313/Apellis Pharmaceuticals announced that detailed data from the phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.The studies evaluated the efficacy and safety of pegcetacoplan, an investigat
- US Eye Adds New Partnerships in Virginia, North Carolina, South Carolina, and Floridahttps://modernod.com/news/us-eye-adds-new-partnerships-in-virginia-north-carolina-south-carolina-and-florida/2480301/The US Eye practice network has recently expanded its practice base to 50 clinics and five surgery centers across the southeastern United States. Financial terms of the deal were not disclosed. US Eye has partnered with Griffey Eye Care located in Chesapeake, Virginia; Al
- Zeiss Introduces New Devices and Software Applications as Part of Medical Ecosystemhttps://modernod.com/news/zeiss-introduces-a-series-of-innovations-and-software-applications-as-part-of-the-medical-ecosystem/2480290/As part of its innovation week, Zeiss introduced integrated solutions designed to bring value to the Zeiss Medical Ecosystem, connecting devices, data, and applications. Zeiss introduced a new integrated cataract workflow solution for lens replacement with the launch of t